Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains.
Biological therapies in multiple myeloma have heralded a new and exciting era for treatment to combat this disease. However the evolutionary pressures that these drugs place on the microenvironment has resulted in a change in the biological behaviour of this malignancy and novel manifestations of relapsed disease. This is illustrated in our series of three patients showing fulminant relapse of disease with plasmablastic features, an extramedullary predilection and a shift in secretion from intact immunoglobulin to free light chains only.
Dawson
Mark A
MA
Patil
Sushrut
S
Spencer
Andrew
A
D000368:Aged; D001536:Bence Jones Protein / Q000652:urine; D002624:Chemistry, Clinical / Q000379:methods; D005260:Female; D006801:Humans; D017578:Immunoglobulin Class Switching; D007147:Immunoglobulin Light Chains / Q000378:metabolism*; D007136:Immunoglobulins / Q000378:metabolism*; D007770:L-Lactate Dehydrogenase / Q000096:biosynthesis; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000473:pathology*; D010950:Plasma Cells / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D012008:Recurrence; D001613:beta 2-Microglobulin / Q000096:biosynthesis
D007147:Immunoglobulin Light Chains; D007136:Immunoglobulins; D012333:RNA, Messenger; D001613:beta 2-Microglobulin; D001536:Bence Jones Protein; D007770:L-Lactate Dehydrogenase